Program Overview
The Best Practice Series in Atherosclerosis is a series of 5-minute videos featuring top physicians discussing the best ways to diagnose and treat atherosclerosis based on the most recent key findings.

New videos will be regularly added to the series to discuss the current literature on the research and treatment of the condition.

The first installment of the Best Practice Series for Atherosclerosis discusses and compares the value of biomarkers in cardiovascular disease. Traditionally, C-Reactive Protein (CRP) has been considered a biomarker of atherosclerosis but in actuality there is no causal relationship between these two entities. Newer biomarkers in atherosclerosis include secretory phospholipase A2 (sPLA2), Lipoprotein-associated phospholipase A2 (LpPLA2) and cytokines.

Faculty and Financial Disclosures
William Borden, MD
Assistant Professor, Medicine and Public Health, Weill Cornell Medical College
Preventive Cardiologist, New York Presbyterian Hospital
Consulting Fees: Kowa Company, Ltd.

Robert Rosenson, MD
Professor, Department of Medicine, State University of New York – Brooklyn
Chief, Endocrinology, Diabetes and Metabolism, State University of New York – Brooklyn
Senior Cardiologist, Department of Medicine, State University of New York – Brooklyn
Consulting Fees: Abbott, Anthera, Astra Zeneca, Daiichi Sankyo, Roche, Xomon
Fees for Non-CME Services: Abbott, AstraZeneca
Contracted Research: Abbott, Anthera, Roche
Ownership Interest: Lipo Science